Stealthy early-stage NVision Medical raises $6.5m

Stealthy NVision Medical raised $6.5 million in a new round of equity financing to support its ovarian cancer diagnostic device, according to an SEC filing. NVision is an early-stage medical device company focused on women’s health, specifically creating in-office diagnostics for ovarian cancer and fallopian tube blockages, according to a 2014 interview with MedCity News. The company was incorporated in 2009, is based in San Francisco, Calif., and is run by founder and CEO Surbhi Sarna. Money in the round came from 17 unnamed sources, and the company is still looking for another $5.5 million before closing, according to an SEC filing. NVision has not yet stated how they plan to use funds from the round. The post Stealthy early-stage NVision Medical raises $6.5m appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Women's Health NVision Source Type: news

Related Links:

Publication date: Available online 15 March 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): V. Lavoue, C. Huchon, C. Akladios, P. Alfonsi, N. Bakrin, M. Ballester, S. Bendifallah, P.A. Bolze, F. Bonnet, C. Bourgin, N. Chabbert-Buffet, P. Collinet, B. Courbiere, T. De la motte rouge, M. Devouassoux-Shisheboran, C. Falandry, G. Ferron, L. Fournier, L. Gladieff, F. GolfierAbstractAn MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (Grade A). In presumed early-stage ovarian or tubal cancers, ...
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
Conclusions: Our results suggest reasonable uptake of risk-reducing interventions in high-risk women. To minimize the occurrence of breast and ovarian cancer in women with a BRCA1 or BRCA2 mutation, more attention could be paid to ensuring that affected women receive proper counselling and follow-up. PMID: 30853805 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
r F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E Abstract Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-a...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
(Abstracted from Lancet Oncol 2018;19:1680–1687) Most women with carcinoma of the ovary, fallopian tube, or peritoneum (tubo-ovarian cancer) present with advanced disease and have a very poor prognosis. An essential therapeutic strategy in these women has been primary debulking surgery (PDS), but no randomized controlled trials have demonstrated an improved prognosis of patients with this strategy.
Source: Obstetrical and Gynecological Survey - Category: OBGYN Tags: GYNECOLOGY: GYNECOLOGIC ONCOLOGY Source Type: research
Rationale: Paraneoplastic dermatomyositis (DM) is an inflammatory disease of the connective tissue caused by immunologic events in the presence of malignant tumors, which are typically related to ovarian, pancreatic, stomach, and colon cancer. Traditional treatment of paraneoplastic DM includes combination therapy for the underlying malignancy with systemic steroids. Patient concerns: A 41-year-old woman presented with facial erythema and myalgia of the extremities. Diagnosis: The patient was diagnosed with DM associated with a fallopian-tube carcinoma. Interventions: The cancer staging surgery was performed via...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
ConclusionsTPP was not associated with increased morbidity compared to SPP. There was a trend towards a longer OS in the TPP group and the finding of residual disease in ‘normal looking’ peritoneum’ warrants prospective evaluation of the benefit of TPP in this setting.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
CONCLUSIONS: The New Zealand rate of referral to genetic counselling for women with high-grade serous cancer, (HGSC), of the ovary, fallopian tube or peritoneum diagnosed between 2015-2016 is encouraging when compared with others internationally. The rate of BRCA positive pathogenic variants is comparable to international data. PMID: 30789886 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
This study provides significant and novel information regarding the frequency, causes, and consequences of elevated FOXM1 expression in human cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
The objectives of this study were to determine both surgical and subsequent cancer outcomes for high-risk women from the University of Virginia's High-Risk Breast/Ovarian Cancer clinic undergoing ovarian cancer risk-reducing surgery. Retrospective review identified high risk women who had ovarian risk reducing surgery over the past decade and surgical outcomes, pathology, pre-operative screening results, and pre-/post-operative cancer diagnoses were evaluated. One hundred and eighty-three high-risk women had risk reducing surgery at a mean age of 50.1 years and with a mean BMI of 28.9 kg/m2 at the time of surgery. Most...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Abstract OBJECTIVE: Despite current guidelines recommending women with ovarian cancer receive genetic risk evaluation by a genetic counselor, utilization has historically been low. We sought to assess the feasibility and effectiveness of a week-long mobile Application for Genetic Information on Cancer (mAGIC) intervention aimed to persuade women with ovarian cancer to pursue genetic counseling. METHODS: The mobile application intervention was based on the Fogg Behavior Model, and consisted of three parts: (1) identifying barriers, (2) developing motivators, and (3) providing triggers to action. The Health Bel...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Fallopian Tube Cancer | Health | Medical Devices | Ovarian Cancer | Ovaries | Women